Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
2023 · Molecular Therapy — Oncolytics · 30 citations
https://doi.org/10.1016/j.omto.2023.07.007
B
Baijin Xia
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
26
Papers
884
Citations
10
h-index
10
i10-index
Baijin Xia is an academic researcher from Guangdong Academy of Medical Sciences. The author has contributed to research in topics: CAR-T cell therapy research & Biomarkers in Disease Mechanisms & Hematological disorders and diagnostics. The author has an h-index of 10, co-authored 23 publications.
ORCID: 0009-0007-2301-2177Papers by this author
worksThe construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments
2024 · Molecular Cancer · 20 citations
https://doi.org/10.1186/s12943-024-01938-8
Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology
2024 · Journal of Translational Medicine · 11 citations
https://doi.org/10.1186/s12967-024-05159-x
Clonal Hematopoiesis of Indeterminate Potential as a Predictor of Colorectal Cancer Risk: Insights from the UK Biobank Cohort
2025 · Cancer Epidemiology Biomarkers & Prevention · 7 citations
https://doi.org/10.1158/1055-9965.epi-24-1342
Development of chimeric Nanobody-Granzyme B functionalized ferritin nanoparticles for precise tumor therapy
2025 · Pharmacological Research · 7 citations
https://doi.org/10.1016/j.phrs.2025.107628
Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation
2024 · Journal of Virology · 1 citations
https://doi.org/10.1128/jvi.01173-24
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat